Verona Pharma

Receive alerts
Market Cap:
£51.08 m
52 weeks high
52 weeks low

Viewing results 1-22 of 22


Arix Bioscience and its portfolio companies set for busy year

There are lots of data readouts and new trial starts pencilled in for the next 18 months...

3 weeks, 3 days ago

Verona Pharma PLC excited about the progress of ensifentrine through clinical trials

Recent trial results support the view that the drug could be an effective bronchodilator in COPD patients via various delivery methods...

on 7/8/19

Verona Pharma: The AIM-quoted drug developer built on the research of a Glaxo legend

Sir David Jack's team were responsible for the discovery of several huge drugs, and RPL554, a compound he helped develop later on in his career, is now being taken through the clinic by Verona...

on 11/7/19

Verona Pharma pushing ahead with development of lead drug despite recent splutter

Verona’s COPD treatment, ensifentrine, failed to meet the primary endpoint in a Phase 2 trial last month, but the results were encouraging enough for the company to keep the faith...

on 26/2/19

Verona Pharma splutters as lead COPD drug disappoints in Phase II study

Ensifentrine was shown to be more effective than a placebo, although it didn’t improve patients’ breathing by as much as hoped...

on 14/1/19

A sixth sense for biotech helps Arix Bioscience turn risk into profit as portfolio value nearly doubles

Analysts at Stifel say the venture capital firm is entering its first extended period of sustained news flow with shares trading at about 45% discount to their £2.53 price target...

on 25/9/18

Synairgen, Verona Pharma and why DCF analysis doesn't provide the full picture

A valuation model is only as good as the data plugged in (or omitted)...

on 11/9/18

Arix Biosciences making progress as well as adding value

Three of Arix's investee companies will be busy in the coming months, while a fourth now has the financial runway to expand its ground-breaking research ...

on 10/8/18

Arix Biosciences' progress significantly undervalued, suggests US broker

Arix’s portfolio companies are involved in 15 clinical trials...

on 2/8/18

Verona Pharma's chief medical officer to quit at the end of the month

The search is already underway for Kenneth Newman's replacement ...

on 11/4/18

NASDAQ listing for Verona Pharma?

Shares rose more than 20% after an oversubscribed placing raised £44.7mln to fund its lung disease drug....

on 20/6/16

Verona Pharma reports progress but losses rise

Drug group reported progress in developing its lung disease treatment...

on 3/6/16